Our privacy policy describes how Fidessa uses cookies on our website. If you continue using our website, you are consenting to our use of cookies. OK

Clear danger ahead

As the regulators push us towards centralised clearing for OTC derivatives they may actually be making the world distinctly less safe. At face value it makes obvious sense; if one party defaults the CCP steps in. As always, though, the problem lies in the detail but this time not too far below the surface.

The first problem concerns the efficient use of margin. As CCPs start to uncouple from their parent exchanges and compete more directly with each other it’s only natural for them to start trying to differentiate more. An obvious step is to offset margin requirements from equivalent (but not fungible) products, especially given the opportunity cost of capital these days. This could now include OTC products and exchange-traded ones, say a Euro-Swap and a Bund. This is OK in principle, but ‘equivalent’ is very different from ‘same’ and a race to the bottom in this type of competitive activity will increase systemic risk rather than reduce it.

The second problem lies in post-trade and allocations. In derivatives this is complicated enough, especially when the executing broker is different from the clearing broker (or brokers) for the actual fund sub-accounts. Now multiply this complexity by the number of SEFs (or OTFs) that emerge, then multiply it again by every clearing house and, finally, throw in the fact that there is no agreed sequence for the messages and you start to get a distinctly queasy feeling.

I think I’ll keep my hard-earned cash under the mattress.

3 Responses to “Clear danger ahead”
  1. Chris says:

    I too considered this on the surface to be good for the markets.
    However, on further analysis this is actually focusing a great deal of global risk in a handful of Clearing Houses. Should a global event happen while the USA and Europe are sleeping, would the Clearing Houses have sufficient funds!!!

  2. Imanol Urquizu says:

    Steve; I agree with you on the first issue but not on the second one. Great tech companies like Fidessa can sure come up with products for allocating and settling all the stuff and details that OTCs will generate…
    thanks for your thoughts… I.

  3. steve grob says:

    Well thanks for the vote of confidence Imanol :) You are right, of course, that technology will need to solve this issue and firms like Fidessa are based on providing workflow that can simplify unnecessary complexity. We have already resolved a bunch of problems in the post trade cash equities world – see http://post-trade.fidessa.com/

    So watch this space !

Leave a comment

Copyright © 2019 Fidessa Group Holdings Limited. All rights reserved.

The information contained within this website is provided for informational purposes only. Fidessa will use reasonable care to ensure that information is accurate at the time it is made available, and for the duration that it remains on the site. The information may be changed by Fidessa at any time without notice. We also reserve the right to close the website at any time. No representation or warranty, expressed or implied, is given on behalf of Fidessa or any of its respective directors, employees, agents, or advisers as to the accuracy or completeness of the information or opinions contained herein or its suitability for any purpose and, save in the case of fraud, all liability for direct, indirect, special, consequential or other loss or damages of whatever kind that may arise from use of the website is hereby excluded to the fullest extent permitted by law. Any decisions you make based on the information in this website are your sole responsibility and information on the website should not be relied upon in connection with any investment decision.

The copyright of this website belongs to Fidessa. All other intellectual property rights are reserved.

Fragulator® is a registered trademark of Fidessa Group Holdings Limited.

Reproduction or redistribution of this information is prohibited except with written permission from Fidessa.